WallStreetZenWallStreetZen

NASDAQ: AVIR
Atea Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Be the first to know when Wall Street analysts revise their AVIR stock forecasts and price targets.

Forecast return on equity

Is AVIR forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.42%

Forecast return on assets

Is AVIR forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

AVIR revenue forecast

What is AVIR's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$68.3M
Avg 2 year Forecast
$40.9M
Avg 3 year Forecast
$120.2M

AVIR vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
AVIR$3.70N/AN/A
MGTX$4.86$11.00+126.34%Buy
ATAI$1.87$10.50+461.50%Strong Buy
LYRA$5.23$11.50+119.89%Strong Buy
IMMP$2.59N/AN/A
View Top Biotech Stocks

Atea Pharmaceuticals Stock Forecast FAQ

What is AVIR's revenue growth forecast for 2024-2026?

(NASDAQ: AVIR) Atea Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.08%.

Atea Pharmaceuticals's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast AVIR's revenue for 2024 to be $5,747,175,955, with the lowest AVIR revenue forecast at $5,747,175,955, and the highest AVIR revenue forecast at $5,747,175,955. On average, 4 Wall Street analysts forecast AVIR's revenue for 2025 to be $3,439,552,461, with the lowest AVIR revenue forecast at $127,088,463, and the highest AVIR revenue forecast at $6,436,062,756.

In 2026, AVIR is forecast to generate $10,114,558,360 in revenue, with the lowest revenue forecast at $7,536,935,005 and the highest revenue forecast at $14,838,209,284.

If you're new to stock investing, here's how to buy Atea Pharmaceuticals stock.

What is AVIR's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: AVIR) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is AVIR's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: AVIR) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.